
Thyroid Cancer - Pipeline Insight, 2025
Description
DelveInsight’s, “Thyroid Cancer - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 51+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Thyroid Cancer: Overview
Thyroid cancer originates in the cells of the thyroid gland, which plays a crucial role in regulating various bodily processes through hormone production. Despite its relatively common occurrence, with over 50,000 new cases reported annually in the United States alone, many people are unaware of its prevalence until it touches someone they know. The disease exhibits a notable gender discrepancy, affecting women at a ratio of three to one, and it can manifest across all age groups, albeit being more prevalent after the age of 30, with a marked increase in aggressiveness among individuals aged 55 and above. Consequently, a significant portion of thyroid cancer patients are women over the age of 30.
Typically, thyroid cancer presents with a nodule on the thyroid, which often remains asymptomatic. It's important to note that the vast majority, over 90%, of thyroid nodules are benign, underscoring the importance of diagnostic procedures. The growth of thyroid cancer almost exclusively occurs within these nodules, rather than affecting the entire thyroid gland itself.
Early stages of thyroid cancer may not elicit noticeable symptoms, with the detection of a neck lump during routine physical examinations being one of the most common indicators. However, it's essential to emphasize that the presence of a lump does not automatically signify cancer, as most thyroid nodules are benign. A biopsy remains the definitive diagnostic tool, wherein small tissue samples are extracted and analyzed for cancerous cells.
Treatment approaches for thyroid cancer are contingent upon various factors, including the cancer type, diagnostic results, stage of advancement, and overall health status. While most thyroid cancers exhibit slow growth and limited metastasis, certain types can display rapid proliferation and dissemination, necessitating prompt and tailored interventions.
""Thyroid Cancer - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Thyroid Cancer pipeline landscape is provided which includes the disease overview and Thyroid Cancer treatment guidelines. The assessment part of the report embraces, in depth Thyroid Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Thyroid Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Thyroid Cancer Emerging Drugs
Further product details are provided in the report……..
Thyroid Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Thyroid Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Thyroid Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Thyroid Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid Cancer drugs.
Thyroid Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Thyroid Cancer: Overview
Thyroid cancer originates in the cells of the thyroid gland, which plays a crucial role in regulating various bodily processes through hormone production. Despite its relatively common occurrence, with over 50,000 new cases reported annually in the United States alone, many people are unaware of its prevalence until it touches someone they know. The disease exhibits a notable gender discrepancy, affecting women at a ratio of three to one, and it can manifest across all age groups, albeit being more prevalent after the age of 30, with a marked increase in aggressiveness among individuals aged 55 and above. Consequently, a significant portion of thyroid cancer patients are women over the age of 30.
Typically, thyroid cancer presents with a nodule on the thyroid, which often remains asymptomatic. It's important to note that the vast majority, over 90%, of thyroid nodules are benign, underscoring the importance of diagnostic procedures. The growth of thyroid cancer almost exclusively occurs within these nodules, rather than affecting the entire thyroid gland itself.
Early stages of thyroid cancer may not elicit noticeable symptoms, with the detection of a neck lump during routine physical examinations being one of the most common indicators. However, it's essential to emphasize that the presence of a lump does not automatically signify cancer, as most thyroid nodules are benign. A biopsy remains the definitive diagnostic tool, wherein small tissue samples are extracted and analyzed for cancerous cells.
Treatment approaches for thyroid cancer are contingent upon various factors, including the cancer type, diagnostic results, stage of advancement, and overall health status. While most thyroid cancers exhibit slow growth and limited metastasis, certain types can display rapid proliferation and dissemination, necessitating prompt and tailored interventions.
""Thyroid Cancer - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Thyroid Cancer pipeline landscape is provided which includes the disease overview and Thyroid Cancer treatment guidelines. The assessment part of the report embraces, in depth Thyroid Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Thyroid Cancer.
This segment of the Thyroid Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Thyroid Cancer Emerging Drugs
- rhTSH: Suzhou Zelgen Biopharmaceuticals
- Nivolumab: Bristol-Myers Squibb
- RX208: Suzhou NeuPharma
- AIC100: AffyImmune Therapeutics
Further product details are provided in the report……..
Thyroid Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Thyroid Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Thyroid Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Thyroid Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Thyroid Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid Cancer drugs.
Thyroid Cancer Report Insights
- Thyroid Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Thyroid Cancer drugs?
- How many Thyroid Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thyroid Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Thyroid Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Thyroid Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- AffyImmune Therapeutics
- Suzhou Zelgen Biopharmaceuticals
- Bristol-Myers Squibb
- Suzhou NeuPharma
- AstraZeneca
- Verastem Oncology
- Thryv Therapeutics
- Molecular Targeting Technologies
- Chimerix
- Codiak BioSciences
- LeadArtis
- Tyra Biosciences
- Roche
- Sichuan Kelun-Biotech Biopharmaceutical
- Advenchen Laboratories
- AIC100
- rhTSH
- Nivolumab
- RX208
- Tremelimumab
- Avutometinib
- THRV-1257
- 177Lu-DOTA-EB-TATE
- Dordaviprone
- exoASO STAT6
- LEAD-472
- Research programme
- Alectinib
- A 400
- AL-2846
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Thyroid Cancer: Overview
- Causes
- Etiology
- Signs and Symptoms
- Disease Treatment/Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Thyroid Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- rhTSH: Suzhou Zelgen Biopharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Nivolumab: Bristol-Myers Squibb
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- AIC100: AffyImmune Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Thyroid Cancer Key Companies
- Thyroid Cancer Key Products
- Thyroid Cancer- Unmet Needs
- Thyroid Cancer- Market Drivers and Barriers
- Thyroid Cancer- Future Perspectives and Conclusion
- Thyroid Cancer Analyst Views
- Thyroid Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.